{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:19:15Z","timestamp":1784920755751,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p><jats:italic>Chlamydia trachomatis<\/jats:italic> (CT) and <jats:italic>Neisseria gonorrhoeae<\/jats:italic> (NG) are the commonest bacterial causes of sexually transmitted infections in humans with high incidence of co-infection. Treatment with high doses of ceftriaxone (CRO) and cefixime (CFM) is strongly recommended due to the reduced drug susceptibility of NG. However, their safety and efficacy have not been confirmed. We compared the safety and efficacy of a single 1\u00a0g intravenous (IV) dose of ceftriaxone (CRO) plus doxycycline (DOX) versus a single 800\u00a0mg oral dose of cefixime (CFM) plus DOX for the treatment of NG-CT co-infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An open-label randomized controlled trial was conducted on 125 individuals aged\u2009&gt;\u200918\u00a0years with untreated gonorrhea and chlamydia to compare a single 1\u00a0g intravenous dose of CRO\u2009+\u2009DOX and a single 800\u00a0mg oral dose of CFM\u2009+\u2009DOX. The primary outcome was the clearance of NG from all the initially infected sites. Secondary outcomes included symptom resolution, changes in the serum clearance levels, glomerular filtration rate, and antibiotic minimum inhibitory concentrations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both regimens were highly effective in treating gonorrhea with success rates of 96.7% (95% confidence interval [CI] 88.8\u201399.1%) for CRO and 95.3% (95% CI 87.1\u201398.4%) for CFM. However, CRO\u2009+\u2009DOX was superior to CFM\u2009+\u2009DOX for the treatment of NG-CT co-infection (odds ratio 4.41, 95% CI 1.11\u201325.7). The safety profiles of the two regimens were similar.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CRO\u2009+\u2009DOX was superior to CFM\u2009+\u2009DOX for the treatment of NG-CT co-infection. CFM\u2009+\u2009DOX may be indicated in patients with CRO allergy and in settings where CRO is unavailable.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov (NCT05216744) on 31\/01\/22.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07595-w","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T09:02:33Z","timestamp":1657357353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct05216744","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Phuong Thi Thu","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Viet","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung Hoang","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Van","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Van","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"key":"7595_CR1","unstructured":"World Health Organization. Report on global sexually transmitted infection surveillance. 2018. https:\/\/www.who.int\/reproductivehealth\/publications\/stis-surveillance-2018\/en\/."},{"key":"7595_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1258\/095646203321156872","volume":"14","author":"S Creighton","year":"2003","unstructured":"Creighton S, Tenant-Flowers M, Taylor CB, Miller R, Low N. Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean? Int J STD AIDS. 2003;14:109\u201313.","journal-title":"Int J STD AIDS"},{"key":"7595_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1\u2013187.","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"7595_CR4","doi-asserted-by":"publisher","first-page":"19792","DOI":"10.2807\/ese.16.06.19792-en","volume":"16","author":"M Unemo","year":"2011","unstructured":"Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 2011;16(6):19792.","journal-title":"Euro Surveill"},{"key":"7595_CR5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/jac\/dkt017","volume":"68","author":"M Yc","year":"2013","unstructured":"Yc M, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013;68:1445\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"7595_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14: e1002344.","journal-title":"PLoS Med"},{"key":"7595_CR7","first-page":"873","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2014United States, 2000\u20132010. MMWR Morb Mortal Wkly Rep. 2011;60:873\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7595_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1258\/ijsa.2009.009198","volume":"23","author":"ZG Bai","year":"2012","unstructured":"Bai ZG, Bao XJ, Cheng WD, Yang KH, Li YP. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. Int J STD AIDS. 2012;23:126\u201332.","journal-title":"Int J STD AIDS"},{"key":"7595_CR9","first-page":"590","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61:590\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7595_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/ijn.12161","volume":"20","author":"E Tugrul","year":"2014","unstructured":"Tugrul E, Khorshid L. Effect on pain intensity of injection sites and speed of injection associated with intramuscular penicillin. Int J Nurs Pract. 2014;20:468\u201374.","journal-title":"Int J Nurs Pract"},{"key":"7595_CR11","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1111\/jocn.13530","volume":"26","author":"D Ozturk","year":"2017","unstructured":"Ozturk D, Baykara ZG, Karadag A, Eyikara E. The effect of the application of manual pressure before the administration of intramuscular injections on students\u2019 perceptions of postinjection pain: a semi-experimental study. J Clin Nurs. 2017;26:1632\u20138.","journal-title":"J Clin Nurs"},{"key":"7595_CR12","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","volume":"393","author":"JDC Ross","year":"2019","unstructured":"Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, Jackson L, Keogh M, Lawrence T, Montgomery AA, Roberts TE, Sprange K, Tan W, Thandi S, White J, Wilson J, Duley L, G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet. 2019;393:2511\u201320.","journal-title":"Lancet"},{"key":"7595_CR13","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1016\/j.vaccine.2018.02.081","volume":"37","author":"LR Vincent","year":"2019","unstructured":"Vincent LR, Jerse AE. Biological feasibility and importance of a gonorrhea vaccine for global public health. Vaccine. 2019;37:7419\u201326.","journal-title":"Vaccine"},{"key":"7595_CR14","first-page":"1","volume":"63","author":"Centers for Disease Control and Prevention","year":"2014","unstructured":"Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae\u20142014. MMWR Recomm Rep. 2014;63:1\u201319.","journal-title":"MMWR Recomm Rep"},{"key":"7595_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1442-2042.2008.02100.x","volume":"15","author":"T Muratani","year":"2008","unstructured":"Muratani T, Inatomi H, Ando Y, Kawai S, Akasaka S, Matsumoto T. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008;15:837\u201342.","journal-title":"Int J Urol"},{"key":"7595_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2012.176575","volume":"309","author":"VG Allen","year":"2013","unstructured":"Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309:163\u201370.","journal-title":"JAMA"},{"key":"7595_CR17","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. http:\/\/www.R-projectorg\/."},{"key":"7595_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/cc2428","volume":"8","author":"V Bewick","year":"2004","unstructured":"Bewick V, Cheek L, Ball J. Statistics review 8: qualitative data\u2014tests of association. Crit Care. 2004;8:46\u201353.","journal-title":"Crit Care"},{"key":"7595_CR19","unstructured":"British Association for Sexual Health and HIV. BASHH clinical effectiveness group guidelines. http:\/\/www.bashh.org\/guidelines. Accessed 18 Dec 2021."},{"key":"7595_CR20","unstructured":"Wang QQ, Zhang R, Liu QZ, et al. National guidelines on diagnosis and treatment of gonorrhea in China (2020). Int J Dermatol Venereol. https:\/\/journals.lww.com\/ijdv\/fulltext\/2020\/09000\/national_guidelines_on_diagnosis_and_treatment_of.1.aspx. Accessed 27 Dec 2021."},{"key":"7595_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/cid\/ciy566","volume":"68","author":"XS Chen","year":"2019","unstructured":"Chen XS, Yin YP, Li XY. A ROADMAP plan to address research needs for gonococcal antimicrobial resistance in China. Clin Infect Dis. 2019;68:505\u201310.","journal-title":"Clin Infect Dis"},{"key":"7595_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jiac.2019.12.001","volume":"27","author":"Hamasuna R, Yasuda M, Takahashi S, Uehara S, Kawai Y, Miyairi I, Arakawa S, Kiyota H, Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy, The JAID\/JSC Guide\/Guidelines to Clinical Management of Infectious Disease Preparing Committee, Sexually Transmitted Infection Working Group","year":"2021","unstructured":"Hamasuna R, Yasuda M, Takahashi S, Uehara S, Kawai Y, Miyairi I, Arakawa S, Kiyota H, Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy, The JAID\/JSC Guide\/Guidelines to Clinical Management of Infectious Disease Preparing Committee, Sexually Transmitted Infection Working Group. The JAID\/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders. J Infect Chemother. 2021;27:546\u201354.","journal-title":"J Infect Chemother"},{"issue":"Suppl 3","key":"7595_CR23","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1086\/511422","volume":"44","author":"LM Newman","year":"2007","unstructured":"Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007;44(Suppl 3):S84-101.","journal-title":"Clin Infect Dis"},{"key":"7595_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/cid\/ciu220","volume":"59","author":"FY Kong","year":"2014","unstructured":"Kong FY, Tabrizi SN, Law M, Vodstrcil LA, Chen M, Fairley CK, Guy R, Bradshaw C, Hocking JS. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59:193\u2013205.","journal-title":"Clin Infect Dis"},{"key":"7595_CR25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/cid\/ciab455","volume":"73","author":"T Aoki","year":"2021","unstructured":"Aoki T, Mizushima D, Takano M, Ando N, Uemura H, Yanagawa Y, Watanabe K, Gatanaga H, Kikuchi Y, Oka S. Efficacy of 1 g ceftriaxone monotherapy compared to dual therapy with azithromycin or doxycycline for treating extragenital gonorrhea among men who have sex with men. Clin Infect Dis. 2021;73:1452\u20138.","journal-title":"Clin Infect Dis"},{"key":"7595_CR26","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1056\/NEJM199111073251903","volume":"325","author":"HH Handsfield","year":"1991","unstructured":"Handsfield HH, McCormack WM, Hook EW 3rd, Douglas JM Jr, Covino JM, Verdon MS, Reichart CA, Ehret JM. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med. 1991;325:1337\u201341.","journal-title":"N Engl J Med"},{"key":"7595_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1177\/1060028020966333","volume":"55","author":"J Dresser","year":"2021","unstructured":"Dresser J, Wilby KJ. Safety of single-dose oral cefixime, intramuscular ceftriaxone, or intramuscular gentamicin for the treatment of gonorrhea: a systematic review and meta-analysis. Ann Pharmacother. 2021;55:914\u201320.","journal-title":"Ann Pharmacother"},{"key":"7595_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1071\/SH10030","volume":"8","author":"CA Renault","year":"2011","unstructured":"Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health. 2011;8:69\u201373.","journal-title":"Sex Health"},{"key":"7595_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034108","volume":"7","author":"NH Dukers-Muijrers","year":"2012","unstructured":"Dukers-Muijrers NH, Morre SA, Speksnijder A, van der Sande MA, Hoebe CJ. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS ONE. 2012;7: e34108.","journal-title":"PLoS ONE"},{"key":"7595_CR30","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1128\/JCM.43.10.5324-5326.2005","volume":"43","author":"DJ Jespersen","year":"2005","unstructured":"Jespersen DJ, Flatten KS, Jones MF, Smith TF. Prospective comparison of cell cultures and nucleic acid amplification tests for laboratory diagnosis of Chlamydia trachomatis infections. J Clin Microbiol. 2005;43:5324\u20136.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07595-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07595-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07595-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T09:03:31Z","timestamp":1657357411000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07595-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7595"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07595-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Hai Phong International Hospital Institutional Review Board. The study was conducted in accordance with the Declaration of Helsinki and International Conference on the Harmonization of the Technical Requirements for the Registration of Pharmaceuticals for Human Use\u2014Good Clinical Practice guidelines and the guideline for Vietnamese Good Clinical Practice. Written informed consent was obtained from all participants before study initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"607"}}